Mubadala Investment Company, in collaboration with CBC Group, has taken full control of UCB Pharma’s mature business in China. This strategic move involves the acquisition of UCB’s neurology and ...

HERZLIYA, Israel and CALGARY, AB, March 7, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its ...

Pharmaceutical companies control and hide ... can take immediate action as part of his prioritization of “radical transparency” to aid his mission to “Make America Healthy Again.” ...

This lack of transparency grants drugmakers incredible power over the decisions of doctors, patients and even governments through controlling the information they see. From 1999 to 2014, ...

The pharmaceutical and cosmetics industries are also leveraging oleogels for their unique textural and stabilizing properties. Unlock Exclusive Insights – Request Your Free Sample Report PDF Now!

Barclays analyst Charles Pitman CFA reiterated a Buy rating on UCB SA (0NZT – Research Report) today and set a price target of €240.00. The company’s shares closed last Friday at €179.89.

Transparency: the key to increasing trust ... academic medical research institutions are the most trusted. For pharma, this means that establishing authentic relationships with trusted and ...

NASHVILLE, Tenn., Feb. 25, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its annual 2024 financial ...

Roth MKM analyst Boobalan Pachaiyappan maintained a Buy rating on Verona Pharma (VRNA – Research Report) today and set a price target of $68.00. The company’s shares closed last Friday at $67.96.

HERZLIYA, Israel and CALGARY, AB, Feb. 18, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a ...